256 related articles for article (PubMed ID: 15780907)
1. Molecular mechanisms of tumor vascularization.
Auguste P; Lemiere S; Larrieu-Lahargue F; Bikfalvi A
Crit Rev Oncol Hematol; 2005 Apr; 54(1):53-61. PubMed ID: 15780907
[TBL] [Abstract][Full Text] [Related]
2. [Rationale of antiangiogenic therapy].
Tímár J; Paku S; Tóvári J; Döme B
Magy Onkol; 2006; 50(2):141-51. PubMed ID: 16888678
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis: basic and clinical aspects.
Ribatti D; Vacca A; Nico B; Presta M; Roncali L
Ital J Anat Embryol; 2003; 108(1):1-24. PubMed ID: 12737512
[TBL] [Abstract][Full Text] [Related]
4. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
Gagne P; Akalu A; Brooks PC
Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
[TBL] [Abstract][Full Text] [Related]
5. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
6. Microtubule-targeting agents in angiogenesis: where do we stand?
Pasquier E; Honoré S; Braguer D
Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139
[TBL] [Abstract][Full Text] [Related]
7. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.
Folkman J
Exp Cell Res; 2006 Mar; 312(5):594-607. PubMed ID: 16376330
[TBL] [Abstract][Full Text] [Related]
9. Use of angiogenesis inhibitors in tumour treatment.
Fayette J; Soria JC; Armand JP
Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
[TBL] [Abstract][Full Text] [Related]
10. [Targeting angiogenesis in oncology].
Fayette J; Soria JC; Armand JP
Pathol Biol (Paris); 2006 May; 54(4):199-205. PubMed ID: 16753494
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparins and angiogenesis.
Norrby K
APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis of angiogenesis and cancer.
Tonini T; Rossi F; Claudio PP
Oncogene; 2003 Sep; 22(42):6549-56. PubMed ID: 14528279
[TBL] [Abstract][Full Text] [Related]
13. Tumour vascularization: sprouting angiogenesis and beyond.
Hillen F; Griffioen AW
Cancer Metastasis Rev; 2007 Dec; 26(3-4):489-502. PubMed ID: 17717633
[TBL] [Abstract][Full Text] [Related]
14. Tumor inflammatory angiogenesis and its chemoprevention.
Albini A; Tosetti F; Benelli R; Noonan DM
Cancer Res; 2005 Dec; 65(23):10637-41. PubMed ID: 16322203
[TBL] [Abstract][Full Text] [Related]
15. [Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].
Cohen-Jonathan Moyal E
Cancer Radiother; 2009 Oct; 13(6-7):562-7. PubMed ID: 19695923
[TBL] [Abstract][Full Text] [Related]
16. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
17. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
Horsman MR; Siemann DW
Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843
[TBL] [Abstract][Full Text] [Related]
18. The role of integrins in tumor angiogenesis.
Hwang R; Varner J
Hematol Oncol Clin North Am; 2004 Oct; 18(5):991-1006, vii. PubMed ID: 15474331
[TBL] [Abstract][Full Text] [Related]
19. A new family of angiogenic factors.
Martínez A
Cancer Lett; 2006 May; 236(2):157-63. PubMed ID: 15927357
[TBL] [Abstract][Full Text] [Related]
20. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
Le Tourneau C; Vidal L; Siu LL
Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
